5.3 Growth Factors & Extracellular Matrix (ECM)

Growth Factors & Extracellular Matrix (ECM)

The progression of wound healing relies upon precise biochemical signaling between soluble cytokines—specifically Growth Factors—and the structural microenvironment known as the Extracellular Matrix (ECM). In healthy tissue repair, a delicate equilibrium exists between matrix degradation and matrix synthesis, regulated by Matrix Metalloproteinases (MMPs) and their endogenous counter-regulators, Tissue Inhibitors of Metalloproteinases (TIMPs). A key focus of the CWS examination is understanding how this biochemical balance fails in chronic non-healing wounds.

---

1. Key Growth Factors in Tissue Repair

Growth Factors are biologically active polypeptides that bind to specific transmembrane cell surface receptors, triggering intracellular signaling cascades that direct cell migration (chemotaxis), proliferation (mitogenesis), differentiation, and protein synthesis.

                 KEY GROWTH FACTORS IN WOUND HEALING
┌──────────┬──────────────────────────────────────────────────────────────┐
│ Factor   │ Primary Cellular Sources & Clinical Functions                │
├──────────┼──────────────────────────────────────────────────────────────┤
│ PDGF     │ Platelets, Macrophages. Recruits PMNs, monocytes &           │
│          │ fibroblasts; initiates granulation tissue deposition.         │
├──────────┼──────────────────────────────────────────────────────────────┤
│ VEGF     │ Endothelial cells, Macrophages. Primary driver of            │
│          │ angiogenesis & vascular permeability.                       │
├──────────┼──────────────────────────────────────────────────────────────┤
│ FGF      │ Fibroblasts, Endothelial cells. bFGF drives angiogenesis;     │
│          │ KGF (FGF-7) stimulates keratinocyte re-epithelialization.    │
├──────────┼──────────────────────────────────────────────────────────────┤
│ TGF-β    │ Platelets, Macrophages, T-cells. Stimulates collagen         │
│          │ synthesis & myofibroblasts; inhibits MMP degradation.        │
├──────────┼──────────────────────────────────────────────────────────────┤
│ EGF      │ Platelets, Salivary/Submaxillary glands. Accelerates         │
│          │ keratinocyte division & epidermal resurfacing.              │
└──────────┴──────────────────────────────────────────────────────────────┘

Platelet-Derived Growth Factor (PDGF)

• Primary Sources: Platelet alpha-granules, macrophages, endothelial cells, smooth muscle cells.
• Functions: Potent chemoattractant for neutrophils, macrophages, and fibroblasts. Stimulates fibroblast proliferation and early ECM synthesis.
• Clinical Application: Recombinant human PDGF-BB (Becaplermin / Regranex) is an FDA-approved topical growth factor indicated for neuropathic diabetic foot ulcers extending into subcutaneous tissue with adequate vascular supply.

Vascular Endothelial Growth Factor (VEGF)

• Primary Sources: Macrophages, keratinocytes, fibroblasts, endothelial cells under hypoxic stress.
• Functions: Specific mitogen for vascular endothelial cells. Induces microvascular permeability and capillary sprout formation during proliferation.

Fibroblast Growth Factor (FGF) Family

• basic FGF (bFGF / FGF-2): Stimulates angiogenesis, endothelial sprouting, and fibroblast proliferation.
• Keratinocyte Growth Factor (KGF / FGF-7): Exclusively acts on epithelial cells; accelerates keratinocyte migration and proliferation across open epidermal deficits.

Transforming Growth Factor-Beta (TGF-β)

• Primary Sources: Platelets, M2 macrophages, T-lymphocytes.
• Functions: Key master regulator of collagen synthesis. It stimulates fibroblasts to produce Types I and III collagen, promotes myofibroblast differentiation for wound contraction, and downregulates MMP production while upregulating TIMPs.
• Pathology: Overexpression of TGF-β1 is strongly implicated in fibrotic disease, hypertrophic scars, and keloids.

Epidermal Growth Factor (EGF) and TGF-α

• Functions: Bind to the EGF receptor (EGFR) on keratinocytes and endothelial cells, accelerating re-epithelialization and epidermal restoration.

---

2. Extracellular Matrix (ECM) Components

The ECM is not merely an inert structural filler; it is a dynamic, instructive 3D microenvironment that modulates cell adhesion, migration, signaling, and mechanical integrity.

                          EXTRACELLULAR MATRIX
                                   │
        ┌──────────────────────────┼──────────────────────────┐
        ▼                          ▼                          ▼
  Structural                Cell Adhesive             Proteoglycans &
   Proteins                 Glycoproteins            Glycosaminoglycans
(Collagen I, III, IV;    (Fibronectin, Laminin,     (Hyaluronic Acid, Decorin,
   Elastin)                   Vitronectin)               Heparan Sulfate)

1. Collagens

Collagen is the most abundant protein in the human body, providing structural tensile strength:

• Type I Collagen: Dominant collagen in dermis, bone, and tendon (~80% of normal adult skin). Provides high tensile strength.
• Type III Collagen: Prevalent in embryonic tissue and early granulation tissue (~30% of early wound matrix). Thin and pliable.
• Type IV Collagen: Key component of the epidermal basement membrane zone (anchors keratinocytes via hemidesmosomes).

Biochemical Requirement: Collagen synthesis requires hydroxylation of proline and lysine residues inside the endoplasmic reticulum. This reaction requires Vitamin C (ascorbic acid), ferrous iron (Fe²⁺), molecular oxygen (O₂), and alpha-ketoglutarate. Scurvy (Vitamin C deficiency) results in un-hydroxylated collagen that cannot form stable triple helices, causing wound dehiscence.

2. Cell-Adhesive Glycoproteins

• Fibronectin: Forms a molecular bridge connecting cell surface integrin receptors to structural collagen fibers, guiding cell migration into the wound bed.
• Laminin: Primary non-collagenous protein of the basement membrane, essential for keratinocyte adhesion and differentiation.

3. Proteoglycans and Glycosaminoglycans (GAGs)

• Hyaluronic Acid (HA): A large, non-sulfated GAG that binds massive amounts of water. HA creates a hydrated, swollen matrix during early inflammation, facilitating cell movement and nutrient diffusion.
• Proteoglycans (e.g., Decorin, Versican, Perlecan): Protein cores with attached GAG chains that bind growth factors (acting as structural reservoirs) and regulate collagen fibrillogenesis.

---

3. MMPs vs. TIMPs Imbalance in Chronic Wounds

Normal tissue repair requires controlled matrix degradation to clear damaged tissue and allow remodeled collagen insertion. This balance is governed by Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases.

Matrix Metalloproteinases (MMPs)

MMPs are a family of zinc-dependent endopeptidases secreted as inactive zymogens (pro-MMPs) by neutrophils, macrophages, fibroblasts, and endothelial cells. They are activated extracellularly by proteolytic cleavage.

• Collagenases (MMP-1, MMP-8): Cleave native triple-helical Type I, II, and III collagens.
• Gelatinases (MMP-2, MMP-9): Degrade denatured collagen (gelatin), Type IV collagen, and fibronectin.
• Stromelysins (MMP-3): Broad substrate specificity; degrade proteoglycans, laminin, and activate other pro-MMPs.

Tissue Inhibitors of Metalloproteinases (TIMPs)

TIMPs (TIMP-1 through TIMP-4) are endogenous proteins secreted by tissue cells that bind covalently to active MMPs in a 1:1 stoichiometric ratio, rendering them enzymatically inactive.

Chronic Wound Pathophysiology: The MMP/TIMP Imbalance

In a healthy acute wound, MMP levels rise transiently to clear debris and allow cell migration, but are rapidly controlled by rising TIMP levels.

In a chronic non-healing wound:

1. Persistent bacterial bioburden and ischemia perpetuate an M1 macrophage and neutrophilic environment.
2. Pro-inflammatory cytokines (TNF-α, IL-1β) remain pathologically elevated.
3. MMP levels increase by 10- to 100-fold compared to acute wounds, while TIMP levels are suppressed or degraded.

ACUTE WOUND (Balanced)               CHRONIC WOUND (Imbalanced / Proteolytic)
   ┌─────────┐   ┌─────────┐            ┌──────────────────┐   ┌───────┐
   │  MMPs   │ = │  TIMPs  │            │       MMPs       │ ≫ │ TIMPs │
   └─────────┘   └─────────┘            │ (10x-100x excess)│   └───────┘
   Controlled Remodeling                └──────────────────┘
                                                  │
                                                  ▼
                                     • Rapid ECM Degradation
                                     • Growth Factor Destruction (PDGF/VEGF cleaved)
                                     • Receptor Cleavage & Cell Senescence
                                     • Stalled Wound Bed

Consequences of Excessive Proteolysis:

• Rapid Degradation of ECM Scaffolding: Newly deposited fibronectin and collagen are destroyed before fibrillogenesis occurs.
• Destruction of Growth Factors: Endogenous (and topically applied) PDGF, VEGF, and TGF-β are cleaved and inactivated within minutes by excess MMP-2, MMP-8, and MMP-9.
• Inactivation of Cell Surface Receptors: Integrin receptors on fibroblasts and keratinocytes are cleaved, rendering cells unresponsive to local signaling cues (cellular senescence).

---

4. Comparison Table: Acute vs. Chronic Wound Fluid Environment

---

5. Clinical Management Strategies for CWS Practitioners

To restore a favorable ECM microenvironment in chronic wounds, CWS clinicians utilize targeted interventions:

1. Maintenance Debridement: Repeated sharp debridement removes senescent cells, bacterial biofilms, and tissue heavily laden with excess MMPs.
2. Advanced ECM Matrix Dressings: Application of collagen-based dressings (e.g., collagen/ORC—oxidized regenerated cellulose) acts as a sacrificial substrate, binding excess MMPs and preserving endogenous growth factors.
3. Bacterial Bioburden Control: Topical antimicrobials and targeted systemic antibiotics suppress cytokine-driven MMP production.